To Buy Right Now 2017: Stocks

+87% (Homebuilders) – Thrived on strong housing demand, low unemployment, and low interest rates.

Small-to-mid cap biotechs saw astronomical gains; Madrigal Pharmaceuticals (MDGL) rose 516% , while Sangamo Therapeutics (SGMO) gained 438% . The Losers: stocks to buy right now 2017

If you tell me more about your , I can narrow this down: +87% (Homebuilders) – Thrived on strong housing demand,

+103% (Healthcare) – Gained on breakthroughs in cystic fibrosis drug trials. Madrigal Pharmaceuticals (MDGL) rose 516%

Hit multi-decade lows, reflecting a remarkably steady upward march. Top 10 S&P 500 Performers of 2017

The only two S&P sectors to finish the year in the red.